Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01476449 · ClinicalTrials.gov registry record · Phase 2
Dosing Study of Ranibizumab for Diabetic Retinal and Macular Edema
A Phase 2 study of Diabetic Retinopathy and Macular Edema, sponsored by Retina Vitreous Associates of Florida.
- Completed
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
- 2
- Study locations
NCT01476449: Completed Phase 2 study of Diabetic Retinopathy and Macular Edema, sponsored by Retina Vitreous Associates of Florida.
NCT01476449 is a Phase 2 study of Diabetic Retinopathy and Macular Edema that has completed, run by Retina Vitreous Associates of Florida. The registered enrollment target is 20 participants, below the 1,676-participant average among 57 other Diabetic Retinopathy trials with a reported enrollment target (99% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01476449, a Phase 2 study of Diabetic Retinopathy and Macular Edema, has completed, sponsored by Retina Vitreous Associates of Florida.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
- 2
- Study locations
Study Summary
This study is to see whether treating diabetic retinal swelling with ranibizumab injections into the eye monthly is better than treating diabetic retinal swelling with ranibizumab injections into the eye less frequently.
Primary Outcome
The ETDRS eye chart was used to assess vision at each visit, with the change through month 24 reported.
Conditions Studied
Interventions
- DRUG Ranibizumab
Study Locations (2)
Florida
- Retina Vitreous Associates of Florida - Clearwater
- Retina Vitreous Associates of Florida - St. Petersburg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2011-11 |
| Est. Completion | 2016-09 |
| Phase | Phase 2 |
What the finished NCT01476449 record still lists
NCT01476449 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 1,676-participant average among 57 other Diabetic Retinopathy trials with a reported enrollment target (99% lower).
The record links to 2 conditions, with Diabetic Retinopathy appearing as the primary indexed condition, and to 1 intervention - of which Ranibizumab is the first listed.
NCT01476449 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT01476449 about?
NCT01476449 is a clinical study titled "Dosing Study of Ranibizumab for Diabetic Retinal and Macular Edema". This study is to see whether treating diabetic retinal swelling with ranibizumab injections into the eye monthly is better than treating diabetic retinal swelling with ranibizumab injections into the eye less frequently.
What is the current status of trial NCT01476449?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2011-11. Estimated completion is 2016-09.
What conditions does trial NCT01476449 study?
This clinical trial studies the following conditions: Diabetic Retinopathy, Macular Edema.
What interventions are being tested in trial NCT01476449?
The interventions under investigation include: Ranibizumab (DRUG).
Who is sponsoring clinical trial NCT01476449?
This trial is sponsored by Retina Vitreous Associates of Florida, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01476449 being conducted?
This trial has 2 study locations across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetic Retinopathy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01476449's enrollment target sits among peer trials
20 50th of 57 higher than 7 of 57 other Diabetic Retinopathy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Diabetic Retinopathy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Test Whether BI 764524 Helps People With an Eye Condition Called Diabetic Retinopathy
RECRUITING · Phase 2
-
A Study to Evaluate the Efficacy and Safety of Orally Administered VX-01
RECRUITING · Phase 2
-
Sleep, Diabetic Retinopathy and Melatonin
RECRUITING · Phase 2
-
4D-150 in Patients With Diabetic Macular Edema
ACTIVE NOT RECRUITING · Phase 2
-
A Study of PER-001 in Participants With Diabetic Retinopathy
ACTIVE NOT RECRUITING · Phase 2
-
Efficacy Study of Lucentis in the Treatment of Diabetic Macular Edema
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia